Stock Traders Buy High Volume of Medtronic Put Options (NYSE:MDT)

Medtronic PLC (NYSE:MDT) saw some unusual options trading activity on Friday. Traders acquired 25,075 put options on the stock. This is an increase of 117% compared to the typical volume of 11,538 put options.

Analyst Ratings Changes

Several research analysts have commented on MDT shares. JPMorgan Chase & Co. cut their price objective on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research report on Thursday, June 4th. Barclays boosted their target price on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Argus cut their price target on Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a report on Monday, April 6th. Wells Fargo & Company reduced their price objective on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Finally, Robert W. Baird decreased their price objective on Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Seventeen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average target price of $99.00.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Several large investors have recently modified their holdings of the stock. Lodestone Wealth Management LLC bought a new stake in Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC boosted its stake in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares during the period. Monetary Solutions Ltd bought a new position in Medtronic during the fourth quarter valued at $27,000. Board of the Pension Protection Fund bought a new position in Medtronic during the fourth quarter valued at $29,000. Finally, GoalVest Advisory LLC bought a new position in Medtronic during the fourth quarter valued at $29,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Medtronic stock opened at $80.94 on Friday. The company’s 50-day moving average price is $79.39 and its 200-day moving average price is $89.74. The company has a quick ratio of 1.87, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The company has a market cap of $103.60 billion, a PE ratio of 21.70, a price-to-earnings-growth ratio of 2.17 and a beta of 0.58. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts forecast that Medtronic will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio is 76.14%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analysts highlighted Medtronic’s positioning in cardiac ablation, diabetes care, and hypertension treatment, including progress with its FDA-approved Symplicity Spyral renal denervation system, which supports the long-term growth story. How Investors May Respond To Medtronic (MDT) Optimism On Renal Denervation Amid Mixed Quantitative Signals
• Positive Sentiment: Medtronic shares have also benefited recently from broad interest around its medical device pipeline and relatively steady operating performance, helping offset some short-term caution.
• Neutral Sentiment: Unusually high options volume suggests traders are positioning for a larger move in MDT, but the direction is not definitive on its own.
• Negative Sentiment: CEO Geoffrey Martha said tariff costs are now expected to total about $250 million in fiscal 2027, which is still a meaningful headwind despite being lower than the prior $300 million estimate. Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company
• Negative Sentiment: Heavy put buying — about 25,075 contracts, well above normal levels — points to bearish sentiment and concern that the shares could weaken further.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).